E7766 Dosing Guidance for OATP Inhibitor Drug Interactions

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The low permeability and active uptake of the anti-cancer compound E7766 lead to potential drug-drug interactions with organic anion transporting polypeptide inhibitors, causing overexposure and adverse effects, which are not effectively managed by existing technologies.

Innovation Solution

A system is provided with containers containing E7766 and accompanying advisories that include information on potential drug-drug interactions, recommending adjusted dosages and administration timing to prevent overexposure by avoiding co-administration or reducing the dose of E7766 when OATP inhibitors are present.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If E7766 is administered to treat cancer, then therapeutic efficacy is improved, but drug-drug interactions with OATP inhibitors cause overexposure and adverse effects

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidoverexposure and adverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The advisory label provides patients and healthcare providers with advance information about potential drug-drug interactions between E7766 and OATP inhibitors. This preliminary information allows for proactive dosage adjustment or avoidance of concomitant administration before harmful interactions occur, preventing overexposure while maintaining therapeutic efficacy.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The system recommends changing dosage parameters when OATP inhibitors are co-administered. Specifically, the dosage of E7766 should be reduced or the administration frequency adjusted to account for decreased clearance caused by OATP inhibition, thereby preventing overexposure while maintaining effective treatment levels.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If E7766 is administered with OATP inhibitors, then comprehensive treatment coverage is improved, but clearance is reduced leading to overexposure

Engineering Contradiction:

Improvecomprehensive treatment coverageVSAvoiddrug exposure level

Core Design Contradiction:

Adaptability or versatilityVSQuantity of substance

Solution Approach 1:

The advisory label creates a feedback mechanism by informing healthcare providers and patients of the interaction risk between E7766 and OATP inhibitors. This feedback enables them to adjust treatment plans, modify dosages, or avoid concomitant administration, thereby controlling exposure levels while maintaining treatment versatility when appropriate.

Inventive Principle:

Principle #23Feedback

3Ease of operation

If standard dosage of E7766 is used, then treatment simplicity is maintained, but patients receiving OATP inhibitors experience overexposure

Engineering Contradiction:

Improvetreatment simplicityVSAvoidadverse events

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The advisory label provides preliminary guidance on dosage adjustment before treatment begins or when OATP inhibitor co-administration is anticipated. This allows healthcare providers to establish appropriate dosing regimens in advance, maintaining treatment simplicity through clear instructions while preventing adverse events through proactive dosage modification.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12564600B2System for enhancing therapeutic compliance of the anti-cancer compound E7766

Publication Date: 2026.03.03 EISAI R&D MANAGEMENT CO LTD

AI summary

Disclosed herein are systems and methods for reducing medication error caused by a drug-drug interaction between Compound 1 (E7766) and an OATP inhibitor. Methods for monitoring the exposure of Compound 1 in a patient and preventing overexposure of Compound 1 in a patient are also disclosed.